

Cochleostomy with Neurovascular Transplant for Meniere's Disease

Policy Number: MCS019.02
Approval Date: August 17, 2021

[Instructions for Use](#)

Table of Contents	Page
Coverage Guidelines	1
Policy History/Revision Information	1
Instructions for Use	1

Related Medicare Advantage Policy Guideline
<ul style="list-style-type: none"> Cochleostomy with Neurovascular Transplant for Meniere's (NCD 50.7)

Coverage Guidelines

Cochleostomy with neurovascular transplant for the treatment of Meniere's disease is not a covered benefit.

Meniere's disease (or syndrome) is a common cause of paroxysmal vertigo. Meniere's syndrome is usually treated medically. When medical treatment fails, surgical treatment may be required.

While there are two recognized surgical procedures used in treating Meniere's disease (decompression of the endolymphatic hydrops and labyrinthectomy), there is no scientific evidence supporting the safety and effectiveness of cochleostomy with neurovascular transplant in treatment of Meniere's syndrome. Accordingly, Medicare does not cover cochleostomy with neurovascular transplant for treatment of Meniere's disease.

Refer to the [NCD for Cochleostomy with Neurovascular Transplant for Meniere's Disease \(50.7\)](#). (Accessed July 26, 2021)

Policy History/Revision Information

Date	Summary of Changes
08/17/2021	<ul style="list-style-type: none"> Routine review; no change to coverage guidelines Archived previous policy version MCS019.01

Instructions for Use

This information is being distributed to you for personal reference. The information belongs to UnitedHealthcare and unauthorized copying, use, and distribution are prohibited. This information is intended to serve only as a general reference resource and is not intended to address every aspect of a clinical situation. Physicians and patients should not rely on this information in making health care decisions. Physicians and patients must exercise their independent clinical discretion and judgment in determining care. Each benefit plan contains its own specific provisions for coverage, limitations, and exclusions as stated in the Member's Evidence of Coverage (EOC)/Summary of Benefits (SB). If there is a discrepancy between this policy and the member's EOC/SB, the member's EOC/SB provision will govern. The information contained in this document is believed to be current as of the date noted.

The benefit information in this Coverage Summary is based on existing national coverage policy; however, Local Coverage Determinations (LCDs) may exist and compliance with these policies are required where applicable.

There are instances where this document may direct readers to a UnitedHealthcare Commercial Medical Policy, Medical Benefit Drug Policy, and/or Coverage Determination Guideline (CDG). In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](#)).

CPT® is a registered trademark of the American Medical Association.